Detailed descriptions of study design, patient eligibility, dose modifications, interruptions, and discontinuations were previously reported 9 and flow cytometry and MRD analyses (flow cytometry and ...

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company focusing on next-generation T cell immunotherapies, announced that CEO Dr. Juan Vera will participate in a live webcast on May 28, ...

In treating aggressive lymphomas and blood cancer (leukemia), chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and ...

The development of conventional T and B lymphocytes is fine and strictly tuned 1. The phenotypical differences between T and B cells are usually thought to be clear, which can be readily discerned ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric leukemia cases. According to REDECAN, more than 400 new cases are estimated to ...

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...

Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...

Marker provides updates supporting the clinical benefits of MT-401 in patients with measurable residual disease (MRD) HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a ...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric leukemia cases. According to REDECAN, more than 400 new cases are estimated to ...